On-treatment monitoring of HBV DNA levels: Predicting response and resistance to oral antiviral therapy at week 24 versus week 48

Hepatology International

Volumn 3, Issue SUPPL.1, 2009, Pages

  Chang, Ting Tsung ^a  

^a NATIONAL CHENG KUNG UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

Antiviral therapy; Chronic hepatitis B; Treatment monitoring

Indexed keywords

EID: 84898013275     PISSN: 19360533     EISSN: 19360541     Source Type: Journal    
DOI: 10.1007/s12072-009-9143-0     Document Type: Review

References (45)

1. Liaw YF, Leung N, Kao JH, Piratvisuth T, Gane E, Han KH, et al., for the Chronic Hepatitis B Guideline Working Party of the Asian-Pacific Association for the Study of the Liver. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2008 update. Hepatol Int 2008;2:263-283
2. Lok AS, McMahon BJ. Chronic hepatitis B. Hepatology 2007;45:507-539 (Pubitemid 46374607)
3. European Association for the Study of the Liver. EASL clinical practice guidelines: management of chronic hepatitis B. J Hepatol 2009;50:227-242
4. Liaw YF, Sung JJ, Chow WC, Farrell G, Lee CZ, Yuen H, et al., for the Cirrhosis Asian Lamivudine Multicentre Study Group. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med 2004;351:1521-1531
5. Lai CL, Gane E, Liaw YF, Hsu CW, Thongsawat S, Wang Y, et al., for the Globe Study Group. Telbivudine versus lamivudine in patients with chronic hepatitis B. N Engl J Med 2007;357:2576-2588 (Pubitemid 350294224)
6. Liaw YF, Gane E, Leung N, Zeuzem S, Wang Y, Lai CL, et al., for the GLOBE Study Group. 2-year GLOBE trial results: telbivudine is superior to lamivudine in patients with chronic hepatitis B. Gastroenterology 2009;136:486-495
7. Zeuzem S, Gane E, Liaw YK, Lim SG, DiBisceglie A, Buti M, et al. Baseline characteristics and early on-treatment response predict the outcomes of 2 years telbivudine treatment of chronic hepatitis B. J Hepatol 2009;51:11-20
8. Bristol Myers-Squibb. Entecavir AVDAC briefing document; 2005. Available from: http://www.fda.gov/OHRMS/DOCKETS/ac/05/briefing/2005-4094B1-01- BristolMyersSquibb-entecavir.pdf. Accessed 1 June 2009
9. Lee HW, Kim HJ, Kim MH, Kim KA, Lee JS, Sul HR, et al. Entecavir induced HBV DNA suppression at 12 weeks in treatment-naive patients with chronic hepatitis B is a good predictive factor for virological response at 48 weeks. Hepatology 2008;48(Suppl):741A. Abstract No.: 969
10. Reijnders JG, Leemans WF, Hansen BE, Pas SD, de Man RA, Schutten M, et al. On-treatment monitoring of adefovir therapy in chronic hepatitis B: virologic response can be assessed at 24 weeks. J Viral Hepat 2009;16:113-120
11. Zöllner B, Schäfer P, Feucht HH, Schröter M, Petersen J, Laufs R. Correlation of hepatitis B virus load with loss of e antigen and emerging drug-resistant variants during lamivudine therapy. J Med Virol 2001;65:659-663 (Pubitemid 33135092)
12. Gauthier J, Bourne EJ, Lutz MW, Crowther LM, Dienstag JL, Brown NA, et al. Quantitation of hepatitis B viremia and emergence of YMDD variants in patients with chronic hepatitis B treated with lamivudine. J Infect Dis 1999;180:1757-1762
13. Yuen MF, Sablon E, Hui CK, Yuan HJ, Decraemer H, Lai CL. Factors associated with hepatitis B virus DNA breakthrough in patients receiving prolonged lamivudine therapy. Hepatology 2001;34:785-791 (Pubitemid 32928004)
14. Hadziyannis A, Mitsoula PV, Hadziyannis SJ. Prediction of long-term maintenance of virologic response during lamivudine treatment in HBeAg negative chronic hepatitis B. Hepatology 2007;46(Suppl):667A
15. Pritchett S, Wong DK, Yim C, Mazzulli T, Heathcote EJ. Factors affecting response to adefovir treatment in patients with chronic hepatitis B and lamivudine resistance. Hepatology 2007; 46(Suppl):675A
16. Heathcote EJ, Gane E, DeMan R, Lee S, Flisiak R, Manns MP, et al. A randomized, double-blind, comparison of tenofovir DF (TDF) versus adefovir dipivoxil (ADV) for the treatment of HBeAg positive chronic hepatitis B (CHB): study GS-US-174-0103. Hepatology 2007;46:861A. Abstract No.: LB7
17. Keeffe EB, Zeuzem S, Koff RS, Dieterich DT, Esteban-Mur R, Gane EJ, et al. Report of an international workshop: roadmap for management of patients receiving oral therapy for chronic hepatitis B. Clin Gastroenterol Hepatol 2007;5:890-897 (Pubitemid 47127032)
18. Papatheodoridis GV, Manolakopoulos S, Archimandritis AJ. Current treatment indications and strategies in chronic hepatitis B virus infection. World J Gastroenterol 2008;14:6902-6910
19. Nguyen MH, Keeffe EB. Chronic hepatitis B: early viral suppression and long-term outcomes of therapy with oral nucleos(t)ides. J Viral Hepat 2009;16:149-155
20. Liaw YF. On-treatment outcome prediction and adjustment during chronic hepatitis B therapy: now and future. Antivir Ther 2009;14:13-22
21. Ghany MG, Strader DB, Thomas DL, Seeff LB, for the American Association for the Study of Liver Diseases. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology 2009;49:1335-1374
22. Asian Pacific Association for the Study of the Liver (APASL) Hepatitis C Working Party. Asian Pacific Association for the Study of the Liver consensus statements of the diagnosis, management and treatment of hepatitis C virus infection. J Gastroenterol Hepatol 2007;22:615-633
23. Kau A, Vermehren J, Sarrazin C. Treatment predictors of a sustained virologic response in hepatitis B and C. J Hepatol 2008;49:634-651
24. van der Eijk AA, Niesters HG, Hansen BE, Heijtink RA, Janssen HLA, Schalm SW, et al. Quantitative HBV DNA levels as an early predictor of nonresponse in chronic HBe-antigen positive hepatitis B patients treated with interferon-alpha. J Viral Hepatol 2006;13:96-103
25. Perrillo RP, Lai CL, Liaw YF, Dienstag JL, Schiff ER, Schalm SW, et al. Predictors of HBeAg loss after lamivudine treatment for chronic hepatitis B. Hepatology 2002;36:186-194 (Pubitemid 34700777)
26. Chan HL, Wang H, Niu J, Chim AM, Sung JJ. Two-year lamivudine treatment for hepatitis B e antigen-negative chronic hepatitis B: a double-blind, placebo-controlled trial. Antivir Ther 2007;12:345-353 (Pubitemid 46787979)
27. Thompson AJ, Ayres A, Yuen L, Bartholomeusz A, Bowden DS, Iser DM, et al. Lamivudine resistance in patients with chronic hepatitis B: role of clinical and virological factors. J Gastroenterol Hepatol 2007;22:1078-1085 (Pubitemid 47019852)
28. Lai CL, Leung N, Teo EK, Tong M, Wong F, Hann HW et al., for the Telbivudine Phase II Investigator Group. A 1-year trial of telbivudine, lamivudine, and the combination in patients with hepatitis B e antigen-positive chronic hepatitis B. Gastroenterology 2005;129:528-536 (Pubitemid 41096641)
29. Yuen MF, Fong DY, Wong DK, Yuen JC, Fung J, Lai CL. Hepatitis B virus DNA levels at week 4 of lamivudine treatment predict the 5-year ideal response. Hepatology 2007;46:1695-1703
30. Tenney DJ, Pokornowski KA, Rose RE, Baldick CJ, Eggers BJ, Fang J, et al. Entecavir maintains a high genetic barrier to HBV resistance through 6 years in naïve patients. J Hepatol 2009; 50(Suppl):S10. Abstract No.: 20
31. Tenney DJ, Rose RE, Baldick CJ, Pokornowski KA, Eggers BJ, Fang J, et al. Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naïve patients is rare through 5 years of therapy. Hepatology 2009;49:1503-1514
32. Colonno RJ, Rose R, Baldick CJ, Levine S, Pokornowski K, Yu CF, et al. Entecavir resistance is rare in nucleoside naïve patients with hepatitis B. Hepatology 2006;44:1656-1665 (Pubitemid 44953670)
33. Tenney DJ, Pokornowski KA, Rose RE, Baldick CJ, Eggers BJ, Fang J, et al. Long-term resistance profile of entecavir in nucleoside-naïve patients with chronic hepatitis B from worldwide and Japanese development programs. Proceedings of the Conference of Hepatitis C and B Virus: Resistance to Antiviral Therapies; 2006 Feb 14-16; Paris, France. Available from: http://www.easl.ch/hepatitis-conference/program/session1.asp. Accessed 2 June 2009
34. Gish RG, Lok AS, Chang TT, de Man RA, Gadano A, Sollano J, et al. Entecavir therapy for up to 96 weeks in patients with HBeAg-positive chronic hepatitis B. Gastroenterology 2007;133: 1437-1444 (Pubitemid 350029745)
35. Han SH, Chang TT, Chao YC, Yoon SK, Gish RG, Cheinquer H, et al. Five years of continuous entecavir for nucleoside-naïve HBeAg(+) chronic hepatitis B: results from study ETV-901. Abstract No.: OP-48. Proceedings of the 13th International Symposium on Viral Hepatitis and Liver Disease; 2009 Mar 20-24; Washington, DC. Available from: http://www.isvhld2009.org/pdfs/sunday- March22-Abstracts.pdf. Accessed 2 June 2009
36. Ma H, Ren JB, Li HY, Wang Y, Wang RL, Liang L, et al. Week 24 suppression of HBV in entecavir-treated chronic hepatitis B patients in whom lamivudine treatment failed is associated with efficacy at week 48. Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi 2007;21:102-104
37. Hsu CW, Chen YC, Liaw YF, Gane E, Manns M, Zeuzem S, et al. Prolonged efficacy and safety of 3 years of continuous telbivudine treatment in pooled data from GLOBE and 015 studies in chronic hepatitis B patients. J Hepatol 2009;50:S331. Abstract No.: 911
38. Marcellin P, Heathcote EJ, Buti M, Gane E, de Man RA, Krastev Z, et al. Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B. N Engl J Med 2008;359:2442-2455
39. Chan HL, Heathcote EJ, Marcellin P, Lai CL, Cho M, Moon YM, et al., for the 018 Study Group. Treatment of hepatitis B e antigen positive chronic hepatitis with telbivudine or adefovir: a randomized trial. Ann Intern Med 2007;147:745-754 (Pubitemid 351664439)
40. Leung N, Peng CY, Hann HW, Sollano J, Lao-Tan J, Hsu CW, et al. Early hepatitis B virus DNA reduction in hepatitis B e antigen-positive patients with chronic hepatitis B: a randomized international study of entecavir versus adefovir. Hepatology 2009;49:72-79
41. Locarnini S, Qi X, Arterburn S, Snow A, Brosgart CL, Currie G, et al. Incidence and predictors of emergence of adefovir resistant HBV during four years of adefovir dipivoxil (ADV) therapy for patients with chronic hepatitis B (CHB). J Hepatol 2005;42 (Suppl):17. Abstract No.: 36
42. Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, Chang TT, Kitis G, Rizzetto M et al., for the Adefovir Dipivoxil 438 Study Group. Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years. Gastroenterology 2006;131:1743-1751 (Pubitemid 44958517)
43. Heathcote J, George S, Gordon JP, Bronowicki J, Sperl R, Williams P, et al. Tenofovir disoproxil fumarate (TDF) for the treatment of HBeAg-positive chronic hepatitis B: week 72 TDF data and week 24 adefovir dipivoxil switch data (study 103). J Hepatol 2008;48:S32. Abstract No.: 72
44. Marcellin P, Jacobson I, Habersetzer F, Senturk H, Andreone P, Moyes C, et al. Tenofovir disoproxil fumarate (TDF) for the treatment of HBeAg-negative chronic hepatitis B: week 72 TDF data and week 24 adefovir dipivoxil switch study (study 102). J Hepatol 2008;48:S26. Abstract No.: 57
45. Snow-Lampart S, Chappell B, Curtis M, Zhu Y, Heathcote J, Marcellin P, et al. Week 96 resistance surveillance for HBeAg positive and negative subjects with chronic HBV infection randomized to receive tenofovir DF 300 mg qd. Abstract No.: OP-82. Proceedings of the 13th International Symposium on Viral Hepatitis and Liver Disease; 2009 Mar 20-24; Washington, DC. Available from: http://www.isvhld2009.org/pdfs/sunday-March22-Abstracts.pdf. Accessed 2 June 2009